A Systematic Review of the Cost and Cost Effectiveness Multidrug-Resistant Tuberculosis

Pharmacoeconomics

30, 63-80

DOI: 10.2165/11595340-000000000-00000

Citation Report

#	Article	IF	Citations
1	WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. European Respiratory Journal, 2011, 38, 516-528.	3.1	718
2	Impact of patient and program factors on default during treatment of multidrug-resistant tuberculosis. International Journal of Tuberculosis and Lung Disease, 2012, 16, 955-960.	0.6	30
3	Cost of tuberculosis in the era of multidrug resistance: will it become unaffordable?. European Respiratory Journal, 2012, 40, 9-11.	3.1	30
5	Ensure a comprehensive approach when treating drug-resistant tuberculosis. Drugs and Therapy Perspectives, 2012, 28, 15-18.	0.3	0
6	Implementing the Global Plan to Stop TB, 2011â€“2015 â€“ Optimizing Allocations and the Global Fundâ€™s Contribution: A Scenario Projections Study. PLoS ONE, 2012, 7, e38816.	1.1	17
7	Decentralisation of multidrug-resistant-tuberculosis care and management. Lancet Infectious Diseases, The, 2013, 13, 644-646.	4.6	12
8	Transmission of multidrug-resistant tuberculosis in the USA: a cross-sectional study. Lancet Infectious Diseases, The, 2013, 13, 777-784.	4.6	27
9	Domestic and donor financing for tuberculosis care and control in low-income and middle-income countries: an analysis of trends, 2002â€“11, and requirements to meet 2015 targets. The Lancet Global Health, 2013, 1, e105-e115.	2.9	39
10	Strategies for reducing treatment default in drug-resistant tuberculosis: systematic review and meta-analysis [Review article]. International Journal of Tuberculosis and Lung Disease, 2013, 17, 299-307.	0.6	119
11	Costs of inpatient treatment for multi-drug-resistant tuberculosis in South Africa. Tropical Medicine and International Health, 2013, 18, 109-116.	1.0	40
12	Universal access to care for multidrug-resistant tuberculosis: an analysis of surveillance data. Lancet Infectious Diseases, The, 2013, 13, 690-697.	4.6	72
13	Multidrug-Resistant Tuberculosis, Somalia, 2010â€“2011. Emerging Infectious Diseases, 2013, 19, 478-480.	2.0	34
14	Upperâ€Room Ultraviolet Germicidal Irradiation (UVGI) for Air Disinfection: A Symposium in Print. Photochemistry and Photobiology, 2013, 89, 764-769.	1.3	27
15	A Systematic Review of the Effectiveness of Hospital- and Ambulatory-Based Management of Multidrug-Resistant Tuberculosis. American Journal of Tropical Medicine and Hygiene, 2013, 89, 271-280.	0.6	63
16	Safety and Efficacy of Delamanid in the Treatment of Multidrug-Resistant Tuberculosis (MDR-TB). Clinical Medicine Insights Therapeutics, 2013, 5, CMT.S11675.	0.4	8
17	Xpert MTB/RIF for diagnosis of tuberculosis and drug-resistant tuberculosis: a cost and affordability analysis. European Respiratory Journal, 2013, 42, 708-720.	3.1	85
18	Economic Evaluation of Diagnosis Tuberculosis in Hospital Setting. , 2013, , .		0
19	Clinical Management of Drug-Resistant Tuberculosis in Resource Constrained Settings. Clinical Medicine Insights Therapeutics, 2013, 5, CMT.S6560.	0.4	0

#	Article	IF	Citations
20	What is the Cost of Diagnosis and Management of Drug Resistant Tuberculosis in South Africa?. PLoS ONE, 2013, 8, e54587.	1.1	187
21	Patterns of Treatment Interruption among Patients with Multidrug-Resistant TB (MDR TB) and Association with Interim and Final Treatment Outcomes. PLoS ONE, 2013, 8, e70064.	1.1	39
22	Health Technology, Quality, Law, and Ethics. , 2014, , 771-819.		4
23	Are We Doing Enough to Stem the Tide of Acquired MDR-TB in Countries with High TB Burden? Results of a Mixed Method Study in Chongqing, China. PLoS ONE, 2014, 9, e88330.	1.1	27
24	Diabetes Mellitus, Smoking Status, and Rate of Sputum Culture Conversion in Patients with Multidrug-Resistant Tuberculosis: A Cohort Study from the Country of Georgia. PLoS ONE, 2014, 9, e94890.	1.1	38
25	Drugâ€resistant tuberculosis: collaborative regional leadership required. Medical Journal of Australia, 2014, 200, 241-242.	0.8	10
26	Cost for Tuberculosis Care in Developed Countries: Which Data for an Economic Evaluation?. Journal of rheumatology Supplement, The, 2014, 91, 83-85.	2.2	1
27	Drug-Resistant Tuberculosis. , 2014, , 1-20.		0
28	Evidence-based, agreed-upon health priorities to remedy the tuberculosis patient's economic disaster. European Respiratory Journal, 2014, 43, 1563-1566.	3.1	36
29	Rapid impact of effective treatment on transmission of multidrug-resistant tuberculosis. International Journal of Tuberculosis and Lung Disease, 2014, 18, 1019-1025.	0.6	117
30	Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. European Respiratory Journal, 2014, 44, 23-63.	3.1	256
31	Interpersonal psychotherapy versus treatment as usual for PTSD and depression among Sichuan earthquake survivors: a randomized clinical trial. Conflict and Health, 2014, 8, 14.	1.0	26
32	Financial burden for tuberculosis patients in low- and middle-income countries: a systematic review. European Respiratory Journal, 2014, 43, 1763-1775.	3.1	423
33	Treatment outcomes from community-based drug resistant tuberculosis treatment programs: a systematic review and meta-analysis. BMC Infectious Diseases, 2014, 14, 333.	1.3	59
34	â€œHome is where the patient isâ€• a qualitative analysis of a patient-centred model of care for multi-drug resistant tuberculosis. BMC Health Services Research, 2014, 14, 81.	0.9	43
35	Weight variation over time and its relevance among multidrug-resistant tuberculosis patients. International Journal of Infectious Diseases, 2014, 23, 20-24.	1.5	19
36	Cost-effectiveness of tuberculosis screening and isoniazid treatment in the TB/HIV in Rio (THRio) Study. International Journal of Tuberculosis and Lung Disease, 2014, 18, 1443-1448.	0.6	19
37	Ambulatory tuberculosis treatment in post-Semashko health care systems needs supportive financing mechanisms. International Journal of Tuberculosis and Lung Disease, 2014, 18, 1390-1395.	0.6	9

#	Article	IF	Citations
38	A case of M anila type M ycobacterium tuberculosis infection in J apan. Clinical Case Reports (discontinued), 2015, 3, 622-625.	0.2	1
39	Cost per patient of treatment for rifampicinâ€resistant tuberculosis in a communityâ€based programme in Khayelitsha, South Africa. Tropical Medicine and International Health, 2015, 20, 1337-1345.	1.0	31
40	The potential of a multiplex high-throughput molecular assay for early detection of first and second line tuberculosis drug resistance mutations to improve infection control and reduce costs: a decision analytical modeling study. BMC Infectious Diseases, 2015, 15, 473.	1.3	4
41	Cost-Effectiveness Analysis of Community Active Case Finding and Household Contact Investigation for Tuberculosis Case Detection in Urban Africa. PLoS ONE, 2015, 10, e0117009.	1.1	47
42	Loss from Treatment for Drug Resistant Tuberculosis: Risk Factors and Patient Outcomes in a Community-Based Program in Khayelitsha, South Africa. PLoS ONE, 2015, 10, e0118919.	1.1	26
43	A bitter pill to swallow: the need for better medications for drug-resistant tuberculosis in children. International Journal of Tuberculosis and Lung Disease, 2015, 19, 55-60.	0.6	12
44	Cost effectiveness of treating multi-drug resistant tuberculosis by adding Deltybaâ„¢ to background regimens in Germany. Respiratory Medicine, 2015, 109, 632-641.	1.3	19
45	Costs to Health Services and the Patient of Treating Tuberculosis: A Systematic Literature Review. Pharmacoeconomics, 2015, 33, 939-955.	1.7	131
46	Use of quality checklists and need for disease-specific guidance in economic evaluations: a meta-review. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 675-685.	0.7	4
47	A tale of two global emergencies: tuberculosis control efforts can learn from the Ebola outbreak. European Respiratory Journal, 2015, 46, 293-296.	3.1	43
48	Treatment interruption and directly observed treatment of multidrug-resistant tuberculosis patients in China. International Journal of Tuberculosis and Lung Disease, 2015, 19, 413-419.	0.6	19
49	Acquisition of second-line drug resistance and extensive drug resistance during recent transmission of Mycobacterium tuberculosis in rural China. Clinical Microbiology and Infection, 2015, 21, 1093.e9-1093.e18.	2.8	12
50	Anti-TB drug resistance in Tanga, Tanzania: A cross sectional facility-base prevalence among pulmonary TB patients. Asian Pacific Journal of Tropical Medicine, 2015, 8, 907-913.	0.4	12
51	Factors Associated with Loss to Follow-up during Treatment for Multidrug-Resistant Tuberculosis, the Philippines, 2012â€“2014. Emerging Infectious Diseases, 2016, 22, 491-502.	2.0	60
52	New Antituberculosis Drugs: From Clinical Trial to Programmatic Use. Gastroenterology Insights, 2016, 8, 6569.	0.7	53
53	Economic evaluation of a shortened standardised treatment regimen of antituberculosis drugs for patients with multidrug-resistant tuberculosis (STREAM): study protocol. BMJ Open, 2016, 6, e014386.	0.8	8
54	More on Treatment Outcomes in Multidrug-Resistant Tuberculosis. New England Journal of Medicine, 2016, 375, 2609-2611.	13.9	9
55	Economic Evaluation in Global Perspective: A Bibliometric Analysis of the Recent Literature. Health Economics (United Kingdom), 2016, 25, 9-28.	0.8	72

#	Article	IF	Citations
56	Variation in policy and practice of adolescent tuberculosis management in the WHO European Region. European Respiratory Journal, 2016, 48, 943-946.	3.1	8
57	Linezolid in the treatment of drug-resistant tuberculosis: the challenge of its narrow therapeutic index. Expert Review of Anti-Infective Therapy, 2016, 14, 901-915.	2.0	62
58	The socioeconomic impact of multidrug resistant tuberculosis on patients: results from Ethiopia, Indonesia and Kazakhstan. BMC Infectious Diseases, 2016, 16, 470.	1.3	47
59	Lobar Collapse Therapy Using Endobronchial Valves as a New Complementary Approach to Treat Cavities in Multidrug-Resistant Tuberculosis and Difficult-to-Treat Tuberculosis: A Case Series. Respiration, 2016, 92, 316-328.	1.2	18
61	Psychosocial wellbeing of patients with multidrug resistant tuberculosis voluntarily confined to long-term hospitalisation in Nigeria. BMJ Global Health, 2016, 1, e000006.	2.0	11
62	Health system support and health system strengthening: two key facilitators to the implementation of ambulatory tuberculosis treatment in Uzbekistan. Health Economics Review, 2016, 6, 28.	0.8	13
63	Community-based management versus traditional hospitalization in treatment of drug-resistant tuberculosis: a systematic review and meta-analysis. Global Health Research and Policy, 2016, 1, 10.	1.4	14
64	WHO strategies for the programmatic management of drug-resistant tuberculosis. Expert Review of Respiratory Medicine, 2016, 10, 991-1002.	1.0	34
65	Rationing tests for drug-resistant tuberculosis â€“ who are we prepared to miss?. BMC Medicine, 2016, 14, 30.	2.3	7
66	Characteristics and costs of multidrug-resistant tuberculosis in-patient care in the United States, 2005â€“2007. International Journal of Tuberculosis and Lung Disease, 2016, 20, 435-441.	0.6	26
67	Health technology assessment in low- and middle-income countries: a landscape assessment. Journal of Pharmaceutical Health Services Research, 2016, 7, 37-42.	0.3	32
68	Diagnostic usefulness of the GenoType MTBDRplusassay for detecting drug-resistant tuberculosis using AFB smear-negative specimens with positive TB-PCR result. Infectious Diseases, 2016, 48, 350-355.	1.4	3
69	Transmission and Institutional Infection Control of Tuberculosis. Cold Spring Harbor Perspectives in Medicine, 2016, 6, a018192.	2.9	62
70	Drug-Resistant Tuberculosis. , 2017, , 263-286.		0
71	The experience of scaling up a decentralized, ambulatory model of care for management of multidrug-resistant tuberculosis in two regions of Ethiopia. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2017, 7, 28-33.	0.6	8
72	The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respiratory Medicine,the, 2017, 5, 291-360.	5.2	459
73	Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries. BMC Health Services Research, 2017, 17, 87.	0.9	23
74	Cost-effectiveness of bedaquiline in MDR and XDR tuberculosis in Italy. Journal of Market Access & Health Policy, 2017, 5, 1283105.	0.8	8

#	Article	IF	Citations
75	Second line drug susceptibility testing to inform the treatment of rifampin-resistant tuberculosis: a quantitative perspective. International Journal of Infectious Diseases, 2017, 56, 185-189.	1.5	14
76	The long and winding road to inhaled TB therapy: not only the bugâ€™s fault. Drug Development and Industrial Pharmacy, 2017, 43, 347-363.	0.9	15
77	Community-based management of multiple drug resistant tuberculosis in a tertiary hospital in Tanzania: a best practice implementation project. JBI Database of Systematic Reviews and Implementation Reports, 2017, 15, 3092-3101.	1.7	2
78	Multidrug-resistant tuberculosis and migration to Europe. Clinical Microbiology and Infection, 2017, 23, 141-146.	2.8	58
79	Systematic reviews of cost-effectiveness in low and middle income countries: a review of reviews. Journal of Development Effectiveness, 2018, 10, 95-120.	0.4	5
80	Benefits and Costs of TB Control for the Post-2015 Development Agenda. , 2018, , 255-265.		1
81	The impact of HIV on the prevalence of asthma in Uganda: a general population survey. Respiratory Research, 2018, 19, 184.	1.4	13
82	MDR-TB patients in KwaZulu-Natal, South Africa: Cost-effectiveness of 5 models of care. PLoS ONE, 2018, 13, e0196003.	1.1	26
83	Improving outcomes for multi-drug-resistant tuberculosis in the Peruvian Amazon â€“ a qualitative study exploring the experiences and perceptions of patients and healthcare professionals. BMC Health Services Research, 2019, 19, 594.	0.9	8
84	Cost of three models of care for drug-resistant tuberculosis patients in Nigeria. BMC Infectious Diseases, 2019, 19, 41.	1.3	12
85	What will it take to eliminate drug-resistant tuberculosis?. International Journal of Tuberculosis and Lung Disease, 2019, 23, 535-546.	0.6	18
86	Cost outcome analysis of decentralized care for drug-resistant tuberculosis in Johannesburg, South Africa. PLoS ONE, 2019, 14, e0217820.	1.1	11
87	Implementation of multidrug-resistant tuberculosis (MDR-TB) treatment in Gabon: lessons learnt from the field. Infection, 2019, 47, 811-816.	2.3	6
88	Reducing tuberculosis transmission: a consensus document from the World Health Organization Regional Office forÂEurope. European Respiratory Journal, 2019, 53, 1900391.	3.1	81
89	Prevalence and associated factors of depression among tuberculosis patients in Eastern Ethiopia. BMC Psychiatry, 2019, 19, 82.	1.1	32
90	Strategic investment in tuberculosis control in the Republic of Bulgaria. Epidemiology and Infection, 2019, 147, e304.	1.0	1
91	Evaluating the Economic Impact of Plastic and Reconstructive Surgical Efforts in the Developing World: The ReSurge Experience. Plastic and Reconstructive Surgery, 2019, 144, 485e-493e.	0.7	10
92	A retrospective analysis of treatment outcomes of drug-susceptible TB in Kazakhstan, 2013â€“2016. Medicine (United States), 2019, 98, e16071.	0.4	3

#	Article	IF	Citations
93	Cost-Effectiveness Analysis of Humanitarian Hand Surgery Trips According to WHO-CHOICE Thresholds. Journal of Hand Surgery, 2019, 44, 93-103.	0.7	19
94	Managing Uncertainties Due to Limited Evidence in Economic Evaluations of Novel Anti-Tuberculosis Regimens: A Systematic Review. PharmacoEconomics - Open, 2020, 4, 223-233.	0.9	1
95	The technological imperative in tuberculosis care and prevention in Vietnam. Global Public Health, 2020, 15, 307-320.	1.0	1
96	Impacts of social support on the treatment outcomes of drug-resistant tuberculosis: a systematic review and meta-analysis. BMJ Open, 2020, 10, e036985.	0.8	16
97	Cost-effectiveness of treating multidrug-resistant tuberculosis in treatment initiative centers and treatment follow-up centers in Ethiopia. PLoS ONE, 2020, 15, e0235820.	1.1	7
100	The health and economic burden of antimicrobial resistance. , 2020, , 23-44.		2
101	Tackling antimicrobial resistance in the community. , 2020, , 45-70.		2
102	The role of vaccines in combating antimicrobial resistance. , 2020, , 181-206.		2
104	Tackling antimicrobial resistance in the hospital sector. , 2020, , 71-98.		0
105	Tackling antimicrobial resistance in the food and livestock sector. , 2020, , 99-124.		1
106	Fostering R&D of novel antibiotics and other technologies to prevent and treat infection. , 2020, , 125-154.		0
107	Ensuring innovation for diagnostics for bacterial infection to combat antimicrobial resistance. , 2020, , 155-180.		0
108	â€œDeath is a better option than being treated like thisâ€¦ a prevalence survey and qualitative study of depression among multi-drug resistant tuberculosis in-patients. BMC Public Health, 2020, 20, 848.	1.2	18
109	Knowledge and attitudes towards ambulatory treatment of tuberculÐ¾sis in Kazakhstan. BMC Health Services Research, 2020, 20, 563.	0.9	2
110	Defining Outcomes of Tuberculosis (Treatment): From the Past to the Future. Respiration, 2021, 100, 843-852.	1.2	8
111	Policy changes and the screening, diagnosis and treatment of drug-resistant tuberculosis patients from 2015 to 2018 in Zhejiang Province, China: a retrospective cohort study. BMJ Open, 2021, 11, e047023.	0.8	3
112	Ambulatory Treatment for Multidrug-Resistant Tuberculosis in Rural Haiti: A Mixed-Methods Study of Social and Economic Factors Affecting Timely Diagnosis and Treatment Success. Global Journal of Health Science, 2021, 13, 99.	0.1	1
113	Costs of multidrug-resistant TB treatment in Finland and Estonia affected by the 2019 WHO guidelines. International Journal of Tuberculosis and Lung Disease, 2021, 25, 554-559.	0.6	5

#	Article	IF	Citations
114	The impact of the stratification by degree of clinical severity and abandonment risk of tuberculosis treatment. Jornal Brasileiro De Pneumologia, 2021, 47, e20210018.	0.4	2
115	Capturing patient-reported and quality of life outcomes with use of shorter regimens for drug-resistant tuberculosis: mixed-methods substudy protocol, TB PRACTECAL-PRO. BMJ Open, 2021, 11, e043954.	0.8	5
116	Challenges to Tackling Antimicrobial Resistance. , 2020, , .		11
117	The role of vaccines in combating antimicrobial resistance. European Journal of Public Health, 2020, 30, .	0.1	2
119	Tuberculosis transmission control: a refocused approach. , 0, , 364-380.		2
120	Scaling-up the Xpert MTB/RIF assay for the detection of tuberculosis and rifampicin resistance in India: An economic analysis. PLoS ONE, 2017, 12, e0184270.	1.1	16
121	Major Infectious Diseases: Key Messages from Disease Control Priorities, Third Edition. , 2017, , 1-27.		28
123	Costâ€“effectiveness of a comprehensive programme for drug-resistant tuberculosis in China. Bulletin of the World Health Organization, 2015, 93, 775-784.	1.5	12
124	Drug resistance TB in India: Challenges, issues and solutions. International Journal of Medical Science and Public Health, 2013, 2, 476.	0.2	0
125	Drug Discovery for TB: Frontiers and Perspectives. , 2014, , 3-31.		1
126	Tackling antimicrobial resistance in the community. European Journal of Public Health, 2020, 30, .	0.1	0
127	Cost-Effectiveness and Cost Utility of Treatment of Attention-Deficit/Hyperactivity Disorder: A Systematic Review. Journal of Child and Adolescent Psychopharmacology, 2021, 31, 578-596.	0.7	7
128	The role of civil society in tackling antimicrobial resistance. , 2020, , 207-240.		0
129	The Progress of Global Antimicrobial Resistance Governance and Its Implication to China: A Review. Antibiotics, 2021, 10, 1356.	1.5	18
130	Minimum inhibitory concentration, pharmacokinetics/pharmacodynamics and therapeutic drug monitoring: An integrated approach for multidrug-resistant tuberculosis. Lung India, 2015, 32, 402-3.	0.3	0
131	Fostering R&D of novel antibiotics and other technologies to prevent and treat infection. European Journal of Public Health, 2020, 30, .	0.1	0
132	The health and economic burden of antimicrobial resistance. European Journal of Public Health, 2020, 30, .	0.1	1
133	Antibiotic drug resistance TB in India. International Journal of Pharmaceutical Chemistry and Analysis, 2022, 8, 145-151.	0.1	1

#	Article	IF	Citations
134	Budgetary impact of using BPaL for treating extensively drug-resistant tuberculosis. BMJ Global Health, 2022, 7, e007182.	2.0	13
136	Cost of TB services in healthcare facilities in Kenya (No 3). International Journal of Tuberculosis and Lung Disease, 2021, 25, 1028-1034.	0.6	10
137	Minimum inhibitory concentration, pharmacokinetics/pharmacodynamics and therapeutic drug monitoring: An integrated approach for multidrug-resistant tuberculosis. Lung India, 2015, 32, 402.	0.3	2
139	TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase IIâ€“III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis. Trials, 2022, 23, .	0.7	22
140	The contribution of drug import to the cost of tuberculosis treatment: A cost analysis of longer, shorter, and short drug regimens for Karakalpakstan, Uzbekistan. PLOS Global Public Health, 2022, 2, e0000567.	0.5	3
141	Cost of TB services: approach and summary findings of a multi-country study (Value TB). International Journal of Tuberculosis and Lung Disease, 2022, 26, 1006-1015.	0.6	5
142	Impacts of Medical Security Level on Treatment Outcomes of Drug-Resistant Tuberculosis: Evidence from Wuhan City, China. Patient Preference and Adherence, 0, Volume 16, 3341-3355.	0.8	2
143	Health technology, quality, law, and ethics. , 2023, , 1037-1095.		0